Capstone Investment Advisors LLC Makes New Investment in R1 RCM Inc. (NASDAQ:RCM)

Capstone Investment Advisors LLC acquired a new position in shares of R1 RCM Inc. (NASDAQ:RCM) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 15,043 shares of the healthcare provider’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Advisors Asset Management Inc. bought a new position in R1 RCM during the first quarter worth about $27,000. GAMMA Investing LLC lifted its position in shares of R1 RCM by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,597 shares of the healthcare provider’s stock worth $37,000 after buying an additional 759 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in R1 RCM by 589.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,122 shares of the healthcare provider’s stock valued at $44,000 after buying an additional 2,669 shares in the last quarter. ANTIPODES PARTNERS Ltd bought a new stake in R1 RCM in the second quarter valued at $86,000. Finally, Values First Advisors Inc. bought a new stake in R1 RCM in the third quarter valued at $88,000. 61.10% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RCM shares. Truist Financial reduced their target price on shares of R1 RCM from $16.00 to $14.30 and set a “hold” rating on the stock in a research note on Thursday, August 8th. Morgan Stanley cut shares of R1 RCM from an “overweight” rating to an “equal weight” rating in a research note on Thursday, August 8th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $14.30 target price on shares of R1 RCM in a research note on Friday, October 4th. Finally, TD Cowen restated a “hold” rating and set a $14.30 price target (down from $20.00) on shares of R1 RCM in a research report on Monday, August 5th. Thirteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $15.41.

R1 RCM Stock Performance

Shares of NASDAQ:RCM opened at $14.31 on Friday. The company has a market capitalization of $6.04 billion, a price-to-earnings ratio of -95.39 and a beta of 0.84. The firm’s 50 day simple moving average is $14.25 and its 200 day simple moving average is $13.53. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.79 and a quick ratio of 1.79. R1 RCM Inc. has a fifty-two week low of $8.87 and a fifty-two week high of $15.12.

R1 RCM (NASDAQ:RCM) last announced its quarterly earnings results on Tuesday, November 5th. The healthcare provider reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). R1 RCM had a negative return on equity of 2.18% and a negative net margin of 2.48%. The firm had revenue of $656.80 million for the quarter, compared to the consensus estimate of $640.93 million. R1 RCM’s revenue for the quarter was up 14.7% compared to the same quarter last year. As a group, sell-side analysts forecast that R1 RCM Inc. will post -0.18 earnings per share for the current year.

R1 RCM Profile

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.